Abstract
This report evaluates 19-norethisterone enanthate (19NEO) in the management of recurrent and metastatic mammary carcinoma. Parmacological effects of the drug are also described. 11 patients were treated with 19NEO 200 mg weekly by injection and 1 was given 560 mg weekly. Urine was collected weekly. Before treatment gonadotrophin excretion varied between 128 and 4 HMG units per 24 hours. During and after treatment this was reduced to less than 10 units in 24 hours in all the patients. In only 1 was there remission of the cancer. In 1 other there may have been an acceleration of the diseases. The excretion of 17-oxosteroids and of 17-hydroxycorticosteroids remained the same. Vaginal smears showed estrogen response in only some patients. Serum concentrations of protein-bound iodine decreased (p less than .05). Radioactive iodine excretion tests showed no consistent change. Serum calcium and excretion of calcium in the urine increased. Metabolic balance studies carried out in 2 patients showed no consistent change in metabolism. Resuts indicated that 19NEO compares unfavorably with nitrogen phosphorus calcium sodium potassium or chloride several other drugs used in the management of advanced breast cancer.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
